Phaseline

Companies › Adicet Therapeutics

Adicet Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Immunology, Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ADI-001
Anti-CD20 CAR-T cell therapy
CD20Phase 1Rheumatoid Arthritis (RA)Mar 2027
ADI-270
anti-CD70 CAR-T cell therapy (engineered gamma-delta Vδ1 T cells)
CD70Phase 1Clear Cell Renal Cell Carcinoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06480565ADI-270Phase 1Clear Cell Renal Cell CarcinomaOncologyJul 2025
NCT07100873ADI-001Phase 1Rheumatoid Arthritis (RA)ImmunologyMar 2027

From the company's SEC filings

Cash of $27m on 2026-09-30; operating cash outflow about $79m a year; runway about 4 months at that burn, to Feb 2027

Press releases filed as 8-K in the last year:

Targets

CD20 (1) CD70 (1)

Companies with the same targets

Chongqing Precision Biotech AstraZeneca Allogene Therapeutics Johnson & Johnson (Janssen) Shanghai Jiaolian Drug Research and Development Lyell Immunopharma Zhejiang Teruisi Pharmaceutical AvenCell Therapeutics Cellectis Biocad

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.